SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-318840"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-318840" > Current Status of R...

Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms

Fani, Melpomeni (författare)
Division of Radiopharmaceutical Chemistry, University Hospital of Basel, 4031 Basel, Switzerland
Peitl, Petra Kolenc (författare)
Department of Nuclear Medicine, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia
Velikyan, Irina, 1966- (författare)
Uppsala universitet,Radiologi,Preparativ läkemedelskemi
 (creator_code:org_t)
2017-03-15
2017
Engelska.
Ingår i: Pharmaceuticals. - : MDPI AG. - 1424-8247. ; 10:1
  • Forskningsöversikt (refereegranskat)
Abstract Ämnesord
Stäng  
  • Nuclear medicine plays a pivotal role in the management of patients affected by neuroendocrine neoplasms (NENs). Radiolabeled somatostatin receptor analogs are by far the most advanced radiopharmaceuticals for diagnosis and therapy (radiotheranostics) of NENs. Their clinical success emerged receptor-targeted radiolabeled peptides as an important class of radiopharmaceuticals and it paved the way for the investigation of other radioligand-receptor systems. Besides the somatostatin receptors (sstr), other receptors have also been linked to NENs and quite a number of potential radiolabeled peptides have been derived from them. The Glucagon-Like Peptide-1 Receptor (GLP-1R) is highly expressed in benign insulinomas, the Cholecystokinin 2 (CCK2)/Gastrin receptor is expressed in different NENs, in particular medullary thyroid cancer, and the Glucose-dependent Insulinotropic Polypeptide (GIP) receptor was found to be expressed in gastrointestinal and bronchial NENs, where interestingly, it is present in most of the sstr-negative and GLP-1R-negative NENs. Also in the field of sstr targeting new discoveries brought into light an alternative approach with the use of radiolabeled somatostatin receptor antagonists, instead of the clinically used agonists. The purpose of this review is to present the current status and the most innovative strategies for the diagnosis and treatment (theranostics) of neuroendocrine neoplasms using a cadre of radiolabeled regulatory peptides targeting their receptors.

Nyckelord

CCK2
GIP
GLP-1R
exendin-4
gastrin
neuroendocrine neoplasms
radiolabeled peptides
somatostatin receptor antagonists
theranostics

Publikations- och innehållstyp

ref (ämneskategori)
for (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...
Fani, Melpomeni
Peitl, Petra Kol ...
Velikyan, Irina, ...
Artiklar i publikationen
Pharmaceuticals
Av lärosätet
Uppsala universitet

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy